Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: A randomized controlled trial

Journal of Clinical Psychiatry

Volumn 78, Issue 7, 2017, Pages e758-e765

  Weiser, Mark ^a,b   Levi, Linda ^a   Burshtein, Shimon ^a   Hagin, Michal ^a   Matei, Valentin P ^c   Podea, Delia ^d   Micluţia, Ioana ^e   Tiugan, Alexandru ^f   Pacala, Bogdan ^g   Grecu, Iosif Gabos ^h   Noy, Adam ⁱ   Zamora, Daisy ^j   Davis, John M ^k  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Spitalul Clinic de Psihiatrie Obregia   (Romania)

^d Clinica de Psihiatrie   (Romania)

^e Spitalul Clinic Judetean de Urgenta Cluj   (Romania)

^f Spitalul Clinic de Urgenta Militar Dr Stefan Odobleja   (Romania)

^g Spitalul Clinic de Psihiatrie Dr Gheorghe Preda   (Romania)

^h Spitalul Clinic Judetean Mures   (Romania)

ⁱ ST GEORGE S HOSPITAL   (United Kingdom)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL RECEPTOR; FOLLITROPIN; FOLLITROPIN RELEASING FACTOR; NEUROLEPTIC AGENT; PLACEBO; RALOXIFENE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DSM-IV-TR; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS;

AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RALOXIFENE HYDROCHLORIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 85028332171     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10498     Document Type: Article

References (51)

1. Seeman MV. The role of estrogen in schizophrenia. J Psychiatry Neurosci. 1996;21(2):123-127.
2. Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry. 1997;42(2):139-151.
3. van der Werf M, Hanssen M, Kohler S, et al; RISE Investigators. Systematic review and collaborative recalculation of 133, 693 incident cases of schizophrenia. Psychol Med. 2014;44(1):9-16.
4. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;28(suppl 2):17-54.
5. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 2001;51(4):317-324.
6. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161(8):1324-1333.
7. Seeman MV. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry. 1983;24(2):125-128.
8. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152(5):698-703.
9. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149(9):1189-1194.
10. Jeste DV, Lindamer LA, Evans J, et al. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull. 1996;32(2):243-251.
11. Magharious W, Goff DC, Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res. 1998;77(3):159-166.
12. Pinals DA, Malhotra AK, Missar CD, et al. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr Res. 1996;22(3):215-222.
13. Angermeyer MC, Kuhn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull. 1990;16(2):293-307.
14. Goldstein JM. Gender differences in the course of schizophrenia. Am J Psychiatry. 1988;145(6):684-689.
15. Harrison G, Croudace T, Mason P, et al. Predicting the long-term outcome of schizophrenia. Psychol Med. 1996;26(4):697-705.
16. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163:183-189.
17. Torgalsboen A.-K. Full recovery from schizophrenia: the prognostic role of premorbid adjustment, symptoms at first admission, precipitating events and gender. Psychiatry Res. 1999;88(2):143-152.
18. Usall J, Araya S, Ochoa S, et al; Assessment Research Group in Schizophrenia (NEDES). Gender differences in a sample of schizophrenic outpatients. Compr Psychiatry. 2001;42(4):301-305.
19. an der Heiden W, Krumm B, Muller S, et al. The Mannheim long-term study of schizophrenia. Initial results of follow-up of the illness over 14 years after initial inpatient treatment [in German]. Nervenarzt. 1995;66(11):820-827.
20. an der Heiden W, et al. Eine prospektive Studie zum Langzeitverlauf schizophrener Psychosen: Ergebnisse der 14-Jahres-Katamnese. ZMP. 1996;5:66-75.
21. Opjordsmoen S. Long-term clinical outcome of schizophrenia with special reference to gender differences. Acta Psychiatr Scand. 1991;83(4):307-313.
22. Weiser M, Reichenberg A, Rabinowitz J, et al. Gender differences in premorbid cognitive performance in a national cohort of schizophrenic patients. Schizophr Res. 2000;45(3):185-190.
23. Hafner H, Behrens S, De Vry J, et al. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res. 1991;38(2):125-134.
24. Moses EL, Drevets WC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry. 2000;48(8):854-860.
25. Perlman WR, Webster MJ, Kleinman JE, et al. Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol Psychiatry. 2004;56(11):844-852.
26. Weickert CS, Miranda-Angulo AL, Wong J, et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet. 2008;17(15):2293-2309.
27. Gonzalez-Burgos I, Rivera-Cervantes MC, Velazquez-Zamora DA, et al. Selective estrogen receptor modulators regulate dendritic spine plasticity in the hippocampus of male rats. Neural Plast. 2012;2012:309494.
28. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90-107.
29. van der Leeuw C, Habets P, Gronenschild E, et al; for G. R. O. U. P. Testing the estrogen hypothesis of schizophrenia: associations between cumulative estrogen exposure and cerebral structural measures. Schizophr Res. 2013;150(1):114-120.
30. Gillies GE, McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev. 2010;62(2):155-198.
31. Chua WL, de Izquierdo SA, Kulkarni J, et al. Estrogen for schizophrenia. Cochrane Database Syst Rev. 2005; (4): CD004719.
32. Begemann MJ, Dekker CF, van Lunenburg M, et al. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res. 2012;141(2-3):179-184.
33. Huang Y, Huang YL, Lai B, et al. Raloxifene acutely reduces glutamate-induced intracellular calcium increase in cultured rat cortical neurons via inhibition of high-voltageactivated calcium current. Neuroscience. 2007;147(2):334-341.
34. Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72(11):1552-1557.
35. Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology. 2010;35(8):1142-1147.
36. Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial. JAMA Psychiatry. 2016;73(9):947-954.
37. Huerta-Ramos E, Iniesta R, Ochoa S, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebocontrolled trial. Eur Neuropsychopharmacol. 2014;24(2):223-231.
38. Weickert TW, Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015;20(6):685-694.
39. Furukawa TA, Levine SZ, Tanaka S, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry. 2015;72(1):14-21.
40. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103.
41. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
42. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Washington, DC: US Department of Health, Education, and Welfare; 1976.
43. Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283-297.
44. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;212:11-19.
45. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand suppl. 1987;334:1-100.
46. Ulrich CM, Potter JD. Folate and cancer. timing is everything. JAMA. 2007;297(21):2408-2409.
47. Weickert TW, Allen KM, Weickert CS. Potential role of oestrogen modulation in the treatment of neurocognitive deficits in schizophrenia. CNS Drugs. 2016;30(2):125-133.
48. Weickert CS, Weickert TW. Hormone modulation improves cognition in schizophrenia. Neuropsychopharmacology. 2016;41(1):384-385.
49. Usall J, Huerta-Ramos E, Labad J, et al; RALOPSYCAT Group. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebocontrolled trial. Schizophr Bull. 2016;42(2):309-317.
50. Labad J, Martorell L, Huerta-Ramos E, et al; RALOPSYCAT Group. Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2016;26(10):1683-1689.
51. Buchanan RW, Keefe RS, Umbricht D, et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011;37(6):1209-1217.